New lipid-lowering drugs help patients reduce LDL cholesterol

August 1, 2016

A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels.

Mutations in the gene that encodes PCSK9 (proprotein convertase subtilisin/kexin type 9) have been linked to . PCSK9 causes elevated blood levels of LDL cholesterol because it binds to the LDL receptor. Two anti-PCSK9 antibodies have recently been approved by the US Food and Drug Administration and the European Medicines Agency: alirocumab and evolocumab.

Researchers identified 12 studies of alirocumab and nine of evolocumab, including more than 10,000 patients, most of whom were taking statins but still had elevated cholesterol. All studies demonstrated a reduction in LDL cholesterol with the anti-PCSK9 antibodies. Up to 87% of patients receiving alirocumab and up to 98% receiving evolocumab reached LDL cholesterol goals.

"Both anti-PSCK9 antibodies have cardiovascular outcome studies ongoing with results expected in 2017. We are looking forward to them since it is rather unusual to have results of large outcome trials so soon after the launch of a drug in the market," said Prof. Ioanna Gouni-Berthold, lead author of the British Journal of Clinical Pharmacology study.

Explore further: PCSK9 monoclonal antibodies show promise in ACS

More information: British Journal of Clinical Pharmacology, DOI: 10.1111/bcp.13066

Related Stories

PCSK9 monoclonal antibodies show promise in ACS

March 23, 2016

(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the ...

Statin intolerance objectively identified in patients

April 3, 2016

In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance ...

Recommended for you

Engineers examine chemo-mechanics of heart defect

June 28, 2017

Elastin and collagen serve as the body's building blocks. They provide tensile strength and elasticity for a number of organs, muscles and tissues. Any genetic mutation short-circuiting their function can have a devastating, ...

Heart attack shown to be 'systemic condition'

June 28, 2017

An acute heart attack should not be viewed in isolation – myocardial infarction is a "systemic" condition with an impact upon the whole body and engenders responses in other organs, such as liver and spleen. That is the ...

Study identifies key player in heart enlargement

June 27, 2017

The heart is a dynamic muscle that grows and shrinks in response to stressors such as exercise and disease. The secret to its malleability lies in individual cells, which get bigger or smaller depending on the heart's needs. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.